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PL-001 USP18 stimulates HCV production and blunts
the antiviral effect of IFNa independent of its
protease activity
L. Chen1 *, J. Sun1, J. Heathcote1, A. Edwards1,
I. McGilvray1. 1University of Toronto, Canada
Background: Combination therapy with pegylated
Interferon and Ribavirin is the best treatment for patients
infected with hepatitis C virus (HCV), but it is only effective
in half of patients. We recently demonstrated that USP18,
the ISG15-speciﬁc protease, is important to HCV responses:
it is one of the 18 gene signature predictive of response
to therapy (Chen et al Gastroenterology 2005, 2010), and
knockdown of USP18 increases the anti-HCV effect of IFNa
(Randall et al Gastroenterology 2006). In this study we
investigated how USP18 protease activity modulates HCV
replication with and without IFNa.
Methods: USP18 wild type (wt) and a protease-inactive
mutant (USP18 C64S, mUSP18) expression constructs were
cloned with an N-terminal GFP tag. Enzymatic activity
of the expressed USP18 was conﬁrmed by co-transfecting
wtUSP18 or mUSP18 with plasmid DNA expressing ISG15-GST
fusion protein. The effect of over-expression of wtUSP18
or mUSP18 on HCVRNA replication/viral particle secretion
with or without IFNa was tested in the J6/JFH1 infectious
culture system.
Results: Over-expression of wtUSP18 in Huh7.5 cells led
to decreased ISGylation in the presence of IFNa, an effect
not seen with overexpression of mUSP18. Overexpression
of both wtUSP18 and mUSP18 increased baseline HCVRNA
replication and production of infectious virus by 4 5 fold;
overexpression of both also blunted the anti-HCV effect of
IFNa. Neither wtUSP18 nor mUSP18 inhibited the expression
of common ISGs (MxA, ISG15, OAS2, Viperin) after exposure
of Huh7.5 cells to IFNa.
Conclusions: USP18 modulates HCV replication and the anti-
HCV activity of IFNa independent of its protease activity
and without disrupting IFNa signaling. These studies reveal
that increased USP18 expression may be one way that
HCV shelters itself from the host response, and should be
considered a target for new anti-HCV therapies.
OL-001 Association study of genetic variation in IL28B
with the hepatitis C treatment-induced viral
clearance in Chinese Han population
X.W. Liao1 *, Y. Ling1, X.H. Li1, Y. Han1, S.Y. Zhang1,
L.L. Gu1, D.M. Yu1, B.L. Yao1, D.H. Zhang1, G.D. Jin1,
Z.M. Lu1, Q.M. Gong1, X.X. Zhang1. 1Department of
Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong
University, School of Medicine, China
Background: Genome-wide association studies have
recently conﬁrmed the rs12979860 variation in IL28B is
associated with the response to chronic hepatitis C (HCV)
treatment. The aim of this study is to investigate whether
the rs12979860 variation could be used as a predictive
marker for end-of-treatment response (ETR) or sustained
virological response (SVR) in Chinese Han population.
Methods: Totally, 259 HCV infected individuals were
detected the rs12979860 genotypes by DNA sequencing.
Among them, 120 patients with complete pegylated
interferon Alfa and ribavirin combination therapy and 92
patients followed for 24 weeks after the cessation of
treatment were divided into different groups according to
outcomes of treatment.
Results: The rs12979860 CC genotype was the main
genotype in Chinese Han patients (87.64%, 227/259) and
only one TT genotype was found in this cohort of patients.
The patients with rs12979860 CC genotype got higher rates
of ETR (P= 0.0044) and SVR (P= 0.0046) than the patients
with N-CC (CT, TT) genotypes. In multiple logistic-regression
models, the rs12979860 variation was associated with a
more substantial difference in rates of achieving ETR (OR:
8.983, CI: 2.173 37.145, P= 0.0024) and SVR (OR: 24.298, CI:
2.272 259.901, P= 0.0083) than the other factors, including
sex, age, HCV genotypes and baseline viral load.
Conclusion: This study demonstrated that the rs12979860
variation in IL28B could be as a predictor for ETR and SVR
in Chinese Han patients with HCV infection.
OL-002 Effect of high-dose ribavirin (RBV), Alinia
(Nitazoxanide) and pegylated interferon
(PegIFN) alfa-2a in attaining sustained virologic
response (SVR) in treatment of chronic
hepatitis C (ERAIS-C Trial) in naı¨ve genotype 1
patients
P.P. Basu1 *, K. Rayapudi2, T. Pacana2, N.J. Shah2,
N. Krishnaswamy2, H. Hampole2, C. Tang2, R. Brown1.
1Columbia University College of Physicians & Surgeons,
New York, NY, USA, 2 Forest Hills Hospital, Forest Hills,
New York, USA
Purpose: PegIFN and Ribavirin (RBV) remain the backbone
of therapy of chronic hepatitis C and achieve a
sustained virologic response (SVR) rate of ~50% globally
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